Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL891780 | 0.91 | POLB (0.33) | POLBTSPO | |
| SCHEMBL891674 | 0.89 | POLB (0.33) | POLB | |
| SCHEMBL891166 | 0.81 | LMNA (0.40) | POLB | |
| SCHEMBL891439 | 0.80 | POLB (0.35) | POLB | |
| SCHEMBL891602 | 0.79 | POLB (0.34) | POLB | |
| SCHEMBL891732 | 0.78 | BCHE (0.38) | POLB | |
| SCHEMBL891685 | 0.77 | POLB (0.34) | POLB | |
| SCHEMBL13161079 | 0.77 | PDE4D (0.52) | POLBTSPO | |
| SCHEMBL891474 | 0.77 | POLB (0.33) | POLB | |
| SCHEMBL891417 | 0.76 | POLB (0.34) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120082645-A1 | 2'-C-METHYL-RIBOFURANOSYL CYTIDINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | XENOPORT, INC. (US) | 2012-04-05 | — | — | US | claimed |
| US-8058260-B2 | 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. (US) | 2011-11-15 | — | — | US | claimed |
| US-20070270374-A1 | 2'-C-Methyl-Ribofuranosyl Cytidine Prodrugs, Pharmaceutical Compositions and Uses Thereof | XENOPORT, INC. | 2007-11-22 | — | — | US | claimed |
| US-20120082645-A1 | 2'-C-METHYL-RIBOFURANOSYL CYTIDINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | XENOPORT, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-8058260-B2 | 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20070270374-A1 | 2'-C-Methyl-Ribofuranosyl Cytidine Prodrugs, Pharmaceutical Compositions and Uses Thereof | XENOPORT, INC. | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082645-A1 | 2'-C-METHYL-RIBOFURANOSYL CYTIDINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MTAP, NSUN2, CDA | POLB 727/4885TSPO 4436/4885 |
| US-20070270374-A1 | 2'-C-Methyl-Ribofuranosyl Cytidine Prodrugs, Pharmaceutical Compositions and Uses Thereof | MTAP, NSUN2, PAICS | POLB 663/4885TSPO 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.